Error in Figure
In the original publication, there was a mistake in Figure 3 as published [1]. We observed that photo B was mistakenly presented in the cisplatin group. However, this photo was from the ellagic acid nano (2 mg/kg) group. So, we changed photo B with another photo from the cisplatin group. This doesn’t change the conclusion made. The corrected Figure 3 appears below.
Figure 3.
Impact of ellagic acid nanoformulation on kidney OAT3 immunoexpression examined in cisplatin-treated rats. (A): Control group; (B): Cisplatin group; (C): Ellagic acid nano (1 mg/kg); and (D): Ellagic acid nano (2 mg/kg). (E): Bar chart showing OAT3 immunoexpression (area %) in the different experimental groups. Results are given as mean ± SE (n = 6). * p ≤ 0.05 relative to the control group; # p ≤ 0.05 relative to cisplatin group; Ω p ≤ 0.05 relative to ellagic acid nano (1 mg/kg) group.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Neamatallah, T.; El-Shitany, N.; Abbas, A.; Eid, B.G.; Harakeh, S.; Ali, S.; Mousa, S. Nano ellagic acid counteracts cisplatin-induced upregulation in OAT1 and OAT3: A possible nephroprotection mechanism. Molecules 2020, 25, 3031. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).